Humasis Co

Humasis Co Payables Turnover

The Payables Turnover Ratio of Humasis Co (205470.KQ) as of Nov 10, 2026 is 104.22. In the previous year, Payables Turnover Ratio was 103.46 — a change of 0.74% (higher).

Payables Turnover

104.22

YoY

0.74%

Last updated:

Payables Turnover Ratio of Humasis Co is 2025 104.22 . Payables Turnover Ratio of Humasis Co was 2024 103.46 . It decreases by 0.74% higher compared to the previous year.

The Humasis Co Payables Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Payables Turnover
Date
Payables Turnover
Jan 1, 2019
7.95 KRW
Jan 1, 2020
6.03 KRW
Jan 1, 2021
3.25 KRW
Jan 1, 2022
34.64 KRW
Jan 1, 2023
111.25 KRW
Jan 1, 2024
103.46 KRW
Jan 1, 2025
104.22 KRW
The Humasis Co Payables Turnover history
YEARPayables TurnoverYoY
104.22+0.74%
103.46-7.01%
111.25+221.21%
34.64+964.65%
3.25-46.06%
6.03-24.08%
7.95—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Payables Turnover Ratio of Humasis Co is 104.22 in 2025.

Payables Turnover Ratio of Humasis Co changed from 103.46 to 104.22, representing a 0.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Payables Turnover Ratio Humasis Co since 2006 – with annual values, charts, and detailed analysis.

Payables turnover measures how quickly a company pays its suppliers. Lower turnover may indicate better payment terms or cash flow management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Payables Turnover Ratio's Humasis Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Payables Turnover Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Payables Turnover Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Humasis Co

All Key Metrics — Humasis Co